Gilhus, N E <br/><br/>
Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence.  [electronic resource] 

 -  European journal of neurology  12 2018 
 - 1402-1409 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1468-1331 
<br/><br/><label>Standard No.: </label>10.1111/ene.13788  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Autoantibodies<br/>Family<br/>Female<br/>Humans<br/>Immunoglobulins, Intravenous--adverse effects<br/>Immunosuppressive Agents--adverse effects<br/>Infant, Newborn<br/>Myasthenia Gravis--drug therapy<br/>Neuromuscular Diseases<br/>Pregnancy<br/>Prenatal Exposure Delayed Effects--immunology<br/>Pyridostigmine Bromide--adverse effects<br/>Receptor Protein-Tyrosine Kinases--immunology<br/>Receptors, Cholinergic--immunology